Related Experiment Video
Updated: Jun 19, 2026
Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
Published on: August 25, 2023
Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients
Zoran Erlic1, Lisa Rybicki, Mariola Peczkowska
1Department of Nephrology, Section of Preventive Medicine, Albert-Ludwigs-University, Hugstetter Strasse 55, Freiburg, Germany.
Insights
Clinical factors can identify patients with pheochromocytoma who need genetic testing for germline mutations. Prioritizing gene sequencing based on these factors reduces costs and improves diagnostic efficiency.
Area of Science:
- Endocrinology
- Genetics
- Oncology
Background:
- Germline mutations in pheochromocytoma susceptibility genes are found in about one-third of patients.
- Genetic testing for four major genes (VHL, RET, SDHB, SDHD) costs approximately $3,400 per patient.
- Identifying which patients require genetic testing and in what order is crucial for efficient diagnosis.
Purpose of the Study:
- To develop a robust algorithm for identifying patients with pheochromocytoma who should undergo genetic testing.
- To determine the optimal order for testing susceptibility genes.
- To reduce the cost of genetic diagnostics for pheochromocytoma.
Main Methods:
- Germline mutations were screened in VHL, RET, SDHB, SDHC, and SDHD genes in 989 apparently nonsyndromic pheochromocytoma patients.
- Clinical parameters were analyzed as predictors for mutation presence using logistic regression and bootstrapping.
- Cost reduction was calculated by comparing prioritized gene testing with testing all genes.
Main Results:
- Of 989 patients, 187 (19%) had germline mutations.
- Predictors for mutations included age <45, multiple pheochromocytomas, extra-adrenal location, and prior head and neck paraganglioma.
- Prioritized testing using a clinical algorithm achieved a 44.7% cost reduction, missing only 4.3% of mutation carriers.
Conclusions:
- Clinical parameters effectively predict mutation carriers in pheochromocytoma.
- A prioritized gene testing strategy based on clinical predictors can significantly reduce diagnostic costs.
- This approach enhances the efficiency of genetic testing for nonsyndromic pheochromocytoma.
Purpose:
Six pheochromocytoma susceptibility genes causing distinct syndromes have been identified; approximately one of three of all pheochromocytoma patients carry a predisposing germline mutation. When four major genes (VHL, RET, SDHB, SDHD) are analyzed in a clinical laboratory, costs are approximately $3,400 per patient. The aim of the study is to systematically obtain a robust algorithm to identify who should be genetically tested, and to determine the order in which genes should be tested.
Experimental Design:
DNA from 989 apparently nonsyndromic patients were scanned for germline mutations in the genes VHL, RET, SDHB, SDHC, and SDHD. Clinical parameters were analyzed as potential predictors for finding mutations by multiple logistic regression, validated by bootstrapping. Cost reduction was calculated between prioritized gene testing compared with that for all genes.
Results:
Of 989 apparently nonsyndromic pheochromocytoma cases, 187 (19%) harbored germline mutations. Predictors for presence of mutation are age <45 years, multiple pheochromocytoma, extra-adrenal location, and previous head and neck paraganglioma. If we used the presence of any one predictor as indicative of proceeding with gene testing, then 342 (34.6%) patients would be excluded, and only 8 carriers (4.3%) would be missed. We were also able to statistically model the priority of genes to be tested given certain clinical features. E.g., for patients with prior head and neck paraganglioma, the priority would be SDHD>SDHB>RET>VHL. Using the clinical predictor algorithm to prioritize gene testing and order, a 44.7% cost reduction in diagnostic process can be achieved.
Conclusions:
Clinical parameters can predict for mutation carriers and help prioritize gene testing to reduce costs in nonsyndromic pheochromocytoma presentations.
More Related Videos
08:57Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
07:15Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenomics: Identification of New Drug Targets
01:27Adrenal Gland Disorders
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...